Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Radu Tanasescu & Cris S Constantinescu. (2014) Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis. Expert Opinion on Drug Metabolism & Toxicology 10:4, pages 621-630.
Read now
Read now
Qingyuan Li & Feng Li. (2010) Effects of different dose of FTY720 on lymphocyte cell cycle arrest in cardiac transplantation model of rats. Immunopharmacology and Immunotoxicology 32:4, pages 680-687.
Read now
Read now
Alejandro Horga, Joaquín Castilló & Xavier Montalban. (2010) Fingolimod for relapsing multiple sclerosis: an update. Expert Opinion on Pharmacotherapy 11:7, pages 1183-1196.
Read now
Read now
Articles from other publishers (33)
Christoph Friedli, Anke Salmen, Robert Hoepner, Lutz Achtnichts, Sandra Bigi, Tobias Derfuss, Claudio Gobbi, Nicole Kamber, Christian P. Kamm, Jens Kuhle, Patrice Lalive, Stefanie Müller, Athina Papadopoulou, Caroline Pot, Chiara Zecca & Andrew Chan. (2022) Specific Aspects of Immunotherapy for Multiple Sclerosis in Switzerland—A Structured Commentary, Update 2022. Clinical and Translational Neuroscience 7:1, pages 2.
Crossref
Crossref
Min Zou, Fang-jun Chen, Li-rong Deng, Qian Han, Chang-yin Huang, Shi-shi Shen, Brian Tomlinson & Yan-hong Li. (2022) Anemoside B4 ameliorates experimental autoimmune encephalomyelitis in mice by modulating inflammatory responses and the gut microbiota. European Journal of Pharmacology 931, pages 175185.
Crossref
Crossref
Faris Zaibaq, Tyrone Dowdy & Mioara Larion. (2022) Targeting the Sphingolipid Rheostat in Gliomas. International Journal of Molecular Sciences 23:16, pages 9255.
Crossref
Crossref
Tamás Biernacki, Dániel Sandi, Judit Füvesi, Zsanett Fricska-Nagy, Tamás Zsigmond Kincses, Péter Ács, Csilla Rózsa, Enikő Dobos, Botond Cseh, László Horváth, Zsuzsanna Nagy, Attila Csányi, Krisztina Kovács, Tünde Csépány, László Vécsei & Krisztina Bencsik. (2022) The safety and efficacy of fingolimod: Real-world data from a long-term, non-interventional study on the treatment of RRMS patients spanning up to 5 years from Hungary. PLOS ONE 17:4, pages e0267346.
Crossref
Crossref
Jonas Asperud, Delmon Arous, Nina Frederike Jeppesen Edin & Eirik Malinen. (2021) Spatially fractionated radiotherapy: tumor response modelling including immunomodulation. Physics in Medicine & Biology 66:17, pages 175012.
Crossref
Crossref
Conor P. Duffy & Claire E. McCoy. (2020) The Role of MicroRNAs in Repair Processes in Multiple Sclerosis. Cells 9:7, pages 1711.
Crossref
Crossref
Amir Valizadeh, Roozbeh Sanaei, Nima Rezaei, Gholamreza Azizi, Saba Fekrvand, Asghar Aghamohammadi & Reza Yazdani. (2019) Potential role of regulatory B cells in immunological diseases. Immunology Letters 215, pages 48-59.
Crossref
Crossref
Tamara Pérez-Jeldres, Christopher J. Tyler, Joshua D. Boyer, Thangaraj Karuppuchamy, Andrés Yarur, Daniel A. Giles, Shaila Yeasmin, Luke Lundborg, William J. Sandborn, Derek R. Patel & Jesús Rivera-Nieves. (2019) Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists. Frontiers in Pharmacology 10.
Crossref
Crossref
Tamara Pérez-Jeldres, Christopher J Tyler, Joshua D Boyer, Thangaraj Karuppuchamy, Giorgos Bamias, Parambir S Dulai, Brigid S Boland, William J Sandborn, Derek R Patel & Jesús Rivera-Nieves. (2019) Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts. Inflammatory Bowel Diseases 25:2, pages 270-282.
Crossref
Crossref
Virginia Garcia‐Martinez, Yolanda Gimenez‐Molina, José Villanueva, Frederic D. Darios, Bazbek Davletov & Luis M. Gutiérrez. (2018) Emerging evidence for the modulation of exocytosis by signalling lipids. FEBS Letters 592:21, pages 3493-3503.
Crossref
Crossref
Luisa Roch, Michael Hecker, Jörg Friess, Ines Charlotte Angerer, Dirk Koczan, Brit Fitzner, Ina Schröder, Kristin Flechtner, Hans-Jürgen Thiesen, Stefanie Meister, Alexander Winkelmann & Uwe Klaus Zettl. (2016) High-Resolution Expression Profiling of Peripheral Blood CD8+ Cells in Patients with Multiple Sclerosis Displays Fingolimod-Induced Immune Cell Redistribution. Molecular Neurobiology 54:7, pages 5511-5525.
Crossref
Crossref
D.-E. Lee, J.-H. Kim, S.-H. Choi, J.-H. Cha, E.-J. Bak & Y.-J. Yoo. (2017) The sphingosine-1-phosphate receptor 1 binding molecule FTY720 inhibits osteoclast formation in rats with ligature-induced periodontitis. Journal of Periodontal Research 52:1, pages 33-41.
Crossref
Crossref
Heather Gwen Mack, Melissa Chih-Hui Tien & Owen Bruce White. (2016) Acute Anterior Uveitis in a Patient Taking Fingolimod (FTY720) for Multiple Sclerosis. Case Reports in Ophthalmology 7:3, pages 562-566.
Crossref
Crossref
Shiri Blumenfeld, Elsebeth Staun-Ram & Ariel Miller. (2016) Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFβ in patients with Multiple Sclerosis. Journal of Autoimmunity 70, pages 40-51.
Crossref
Crossref
Loubna Abdel Hadi, Clara Di Vito, Giovanni Marfia, Stefania Elena Navone, Rolando Campanella & Laura Riboni. 2015. Bioactive Sphingolipids in Cancer Biology and Therapy. Bioactive Sphingolipids in Cancer Biology and Therapy
259
293
.
M. Stenovec, S. Trkov, M. Kreft & R. Zorec. (2014) Alterations of calcium homoeostasis in cultured rat astrocytes evoked by bioactive sphingolipids. Acta Physiologica 212:1, pages 49-61.
Crossref
Crossref
A Salmen, R Gold & A Chan. (2014) Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system. Clinical and Experimental Immunology 176:2, pages 135-148.
Crossref
Crossref
Young-Jin SeoBumsuk Hahm. (2014) Sphingosine Analog AAL-R Promotes Activation of LCMV-Infected Dendritic Cells. Viral Immunology 27:2, pages 82-86.
Crossref
Crossref
Jonathan P. McNally, Eileen E. Elfers, Catherine E. Terrell, Eli Grunblatt, David A. Hildeman, Michael B. Jordan & Jonathan D. Katz. (2014) Eliminating Encephalitogenic T Cells without Undermining Protective Immunity. The Journal of Immunology 192:1, pages 73-83.
Crossref
Crossref
Madhuvanthi Vijayan & Bumsuk Hahm. (2014) Influenza Viral Manipulation of Sphingolipid Metabolism and Signaling to Modulate Host Defense System. Scientifica 2014, pages 1-9.
Crossref
Crossref
Mariangela Urbano, Miguel Guerrero, Hugh Rosen & Edward Roberts. (2013) Modulators of the Sphingosine 1-phosphate receptor 1. Bioorganic & Medicinal Chemistry Letters 23:23, pages 6377-6389.
Crossref
Crossref
Young-Jin Seo, Curtis J. Pritzl, Madhuvanthi Vijayan, Celeste R. Blake, Mariah E. McClain & Bumsuk Hahm. (2012) Sphingosine Analogue AAL-R Increases TLR7-Mediated Dendritic Cell Responses via p38 and Type I IFN Signaling Pathways. The Journal of Immunology 188:10, pages 4759-4768.
Crossref
Crossref
Colleen E. Miller & Margaret A. Umhauer. (2011) Emerging Oral Therapies for Multiple Sclerosis. Journal of Neuroscience Nursing 43:1, pages 3-14.
Crossref
Crossref
Young-Jin Seo, Stephen Alexander & Bumsuk Hahm. (2011) Does cytokine signaling link sphingolipid metabolism to host defense and immunity against virus infections?. Cytokine & Growth Factor Reviews 22:1, pages 55-61.
Crossref
Crossref
O. Aktas, J. Ingwersen, B. Kieseier, P. Küry, R. Hohlfeld & H.-P. Hartung. (2010) Orales Fingolimod bei Multipler SkleroseOral fingolimod in multiple sclerosis. Der Nervenarzt 82:2, pages 215-225.
Crossref
Crossref
Donald J. AbrahamDonna M. Huryn. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
547
568
.
Young-Jin Seo, Celeste Blake, Stephen Alexander & Bumsuk Hahm. (2010) Sphingosine 1-Phosphate-Metabolizing Enzymes Control Influenza Virus Propagation and Viral Cytopathogenicity. Journal of Virology 84:16, pages 8124-8131.
Crossref
Crossref
Gavin Giovannoni. (2010) Recent developments in oral medications for the treatment of multiple sclerosis. Future Neurology 5:2, pages 167-172.
Crossref
Crossref
Wenyan Miao & Lijun Wu. 2009. Enzyme Inhibition in Drug Discovery and Development. Enzyme Inhibition in Drug Discovery and Development
625
667
.
Meryem Bektas, Stewart P. Johnson, William E. Poe, Darell D. Bigner & Henry S. Friedman. (2009) A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells. Cancer Chemotherapy and Pharmacology 64:5, pages 1053-1058.
Crossref
Crossref
Dong-Soon Im. (2009) New intercellular lipid mediators and their GPCRs: An update. Prostaglandins & Other Lipid Mediators 89:3-4, pages 53-56.
Crossref
Crossref
Kazuo Kamada, Norimasa Arita, Takahito Tsubaki, Nobuo Takubo, Takahiro Fujino, Yoshiko Soga, Tatsuhiko Miyazaki, Haruyasu Yamamoto & Masato Nose. (2009) Expression of sphingosine kinase 2 in synovial fibroblasts of rheumatoid arthritis contributing to apoptosis by a sphingosine analogue, FTY720. Pathology International 59:6, pages 382-389.
Crossref
Crossref
Sujoy Lahiri, Hyejung Park, Elad L. Laviad, Xuequan Lu, Robert Bittman & Anthony H. Futerman. (2009) Ceramide Synthesis Is Modulated by the Sphingosine Analog FTY720 via a Mixture of Uncompetitive and Noncompetitive Inhibition in an Acyl-CoA Chain Length-de pend ent Manner. Journal of Biological Chemistry 284:24, pages 16090-16098.
Crossref
Crossref